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Several adult stem cell types have been found in different parts of the eye, including the corneal epithelium, conjunctiva, and
retina. In addition to these, there have been accumulating evidence that some stem-like cells reside in the transition area between
the peripheral corneal endothelium (CE) and the anterior nonfiltering portion of the trabecular meshwork (TM), which is known
as the Schwalbe’s Ring region. These stem/progenitor cells may supply new cells for the CE and TM. In fact, the CE and TM share
certain similarities in terms of their embryonic origin and proliferative capacity in vivo. In this paper, we discuss the putative
stem cell source which has the potential for replacement of lost and nonfunctional cells in CE diseases and glaucoma. The future
development of personalized stem cell therapies for the CE and TM may reduce the requirement of corneal grafts and surgical
treatments in glaucoma.
1. Introduction
Rapid progress in stem cell research in recent years provides
new hope for the treatment of various previously incurable
diseases. The basic treatment principle is to replace lost or
damaged cells with healthy ones derived from stem cells
and/or stimulate endogenous regeneration via paracrine
effects mediated by the transplanted stem cells [1, 2].
Stem cells can reasonably be categorized into three main
types according to their origins: embryonic stem (ES) cells,
induced pluripotent stem cells (iPSCs), and adult stem cells.
The focus of this paper will concern a specific region of
the eye, namely, the adult stem cells of the human corneal
endothelium (CE) and neighbouring trabecular meshwork
(TM), there will be considerable overlap in the techniques
applied to the differentiation of cells and obstacles to be
addressed before regeneration therapies are available.
2. Stem Cell Overview
Whilst ES cells have numerous advantages in research such
as their unlimited capacity to self-renew and pluripotency
allowing them to differentiate into any cell type in the body,
the fear of teratoma formation, immune-rejection issues, and
ethical concerns regarding the destruction of embryos have
slowed their progress towards clinical trials.
The research field of iPSCs has rapidly gained momen-
tum since the discovery by Takahashi and Yamanaka [3].
iPSCs afford an advantage in that an autologous approach
may be possible and as such circumventing the ethical and
immunological disadvantages of ES cells. However, there
are major safety concerns that involvement of retroviral or
lentiviral vector integration in iPSCs engineering may cause
genomic disruption and oncogenesis [4–6]. Besides, after
the reports proving iPSCs retained epigenetic memory from
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the somatic cell of origin [7, 8], questions have been raised
whether iPSCs are completely pluripotent like ES cells, as
how far back they are reprogrammed will influence their
directed differentiation potential. Despite the bright future
iPSCs may have, extensive efforts and a measured scientific
approach are required to guarantee safety and production
quality, to understand more about the molecular signaling
and pathways, and to find out reliable differentiation proto-
cols of iPSCs before transplantation can be done in patients.
Adult stem or progenitor cells are also referred to as
somatic stem cells. They reside in many adult tissues such
as the bone marrow, skeletal muscle, heart, brain, skin, and
limbus (summarized in [9]). Although they are not plurip-
otent, they still retain high plasticity. Their ethical superior-
ity over embryonic stem cells and autologous origin avoiding
immunological suppression after surgery makes them a pop-
ular stem cell source for small-scale clinical application
[10, 11]. Adult stem cells are enriched in locations that are
very close to the target tissue, as such, they may have more
direct and faster access to the site of injury when com-
pared with other stem cell types [9]. In addition, they
have already undergone critical developmental stages, which
render them comparatively easier to commit to the cell
types desired [12, 13]. Understandably, difficulties such
as their isolation, expansion efficiency due to limited cell
numbers and integration and survival in the host tissue still
remain to be unravelled. Adult stem cells, albeit with their
own limitations, may be a relatively safer and more ethical
alternative cell source for therapeutic use at present.
In the eye, the most successful stem-cell-based therapy to
date has been the use of limbal epithelial stem cells to
regenerate the corneal epithelium [14]. Apart from limbal
epithelial stem cells, intensive research has been done on
different niches of adult ocular stem cells, such as conjunc-
tival epithelial and retinal stem cells, aiming for ocular repair
and regeneration [13, 15, 16]. One niche of cells that has
had relatively limited attention and may be of considerable
clinical value (which is the focus of this paper) are the
progenitor cells located in the transition zone between the
periphery of the CE and the anterior extension of the TM,
which is known as the Schwalbe’s Ring region. In the recent
decade, more and more evidence emerged to support the
idea that these progenitors may be able to provide new cells
for the CE, TM, or possibly both. This opens up a new
prospect on research using these intriguing progenitors to
treat CE diseases and glaucoma. In this paper, we will review
the biological properties of CE and TM cells, summarize and
discuss the evidence suggesting the presence of stem-like cells
in the transition area, and, in addition, outline how these
cells can be used for regeneration.
3. CE and TM: Structure, Function,
and Embryology
3.1. Corneal Endothelium. Cornea is the transparent tissue
located at the front of the eye which provides approximately
two-thirds of the total ocular refractive power (Figure 1(a)).
It consists of five layers: the multilayered epithelium,
Bowman’s membrane, the stroma, Descemet’s membrane,
and the endothelium. CE is on the posterior surface of the
cornea facing the anterior chamber. It is composed of a
single layer of regularly arranged hexagonal and pentagonal
cells which are around 5 μm thick and 20 μm in diameter
[17]. The crucial function of the CE is to maintain corneal
transparency by regulating corneal hydration while allowing
nutrients from the aqueous to diffuse back to the avascular
cornea. The endothelium accomplishes this by a pump-
leak model. It serves as a “leaky” barrier to permit selective
permeability of the nutrients but prevents bulk fluid flow
into the stroma. At the same time, it actively removes excess
fluid from the stroma into the anterior chamber through
ionic fluid pumps to prevent corneal swelling. In addition
to the barrier and pump functions, the endothelial cells are
responsible for the synthesis of Descemet’s membrane, which
is the basement membrane where the endothelium resides
[18, 19].
3.2. Trabecular Meshwork. The anterior chamber of the eye
is bordered anteriorly by the CE and posteriorly by the iris.
At the periphery of the chamber, there lie the TM, scleral
spur, ciliary body, and iris root, which form the anterior
chamber angle (Figure 1(b)). The TM extends from an
anatomical position called Schwalbe’s line, which marks the
end of Descemet’s membrane, to the ciliary body and iris
root at their junction. There is a specific cell population
near the transition area (Schwalbe’s line) between cornea and
meshwork, and this will be discussed in detail in Section 5.
Together with Schlemm’s canal, the collector channels, and
aqueous veins, the TM forms themajor structure for aqueous
humour outflow [17]. Aqueous humour is produced by the
ciliary body and passes through the pupil into the anterior
chamber. It subsequently leaves the eye through the TM into
Schlemm’s canal, then from there to the intrascleral plexus,
and finally to the episcleral venous system [20].
The TM is a porous tissue comprised of three regions: the
innermost uveal meshwork which is chord-like in structure,
the deeper corneoscleral meshwork with flattened sheet-like
trabeculae, and the juxtacanalicular connective tissue (also
called cribriform layer or endothelial meshwork) which links
the corneoscleral trabeculae with the inner wall endothelium
of Schlemm’s canal [17, 21]. The trabecular lamellae or
beams contain collagenous cores surrounded by endothelial
cells, and the lamellae are bridged by the TM cells [22].
The corneoscleral and uveal meshwork do not provide
much resistance to aqueous outflow and Grant showed that
aqueous outflow facility was not affected even if the inner
parts of the TM were excised [23]. The outflow resistance
resides primarily at the region near the juxtacanalicular
connective tissue and the endothelial lining of Schlemm’s
canal [22]. Since the Schlemm’s canal is shorter than the TM
in the anteroposterior direction, the TM can also be divided
into the anterior nonfiltering and posterior filtering portions.
3.3. Embryology. During embryogenesis, the neural ecto-
derm, the surface ectoderm, the neural crest, and, to a lesser
extent, the mesoderm are involved in the development of
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Figure 1: (a) Schematic diagram of the human eye and transverse section of haematoxylin and eosin stained chamber angle tissues (×100).
(b) Anterior chamber angle as viewed in gonioscopy.
the eye. The CE and TM are both derived from the neural
crest. They are formed from the first wave of neural crest-
derived mesenchymal cells migrating between the surface
ectoderm and the lens. The development of the cornea begins
at approximately 33 days of postfertilization [24]. At around
the 40th day, a double row of flattened cells posterior to the
basal lamina of the corneal epithelium is produced by the
mesenchyme and it develops into the monolayer of CE by
the 18th week [18, 24, 25]. At this time, the CE extends nearly
to the angle recess. This endothelial membrane covering the
angle recess starts to regress at around 15 weeks of gestation
[25].
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The primitive TM is formed at around the fourth month.
It consists of a triangular mass of undifferentiated mes-
enchymal cells. During the seventh month, these cells flatten
and become slightly separated from each other, and the
cavities are filled with extracellular fibers. The fibers are then
organized to form the trabecular lamellae or beams. Some
cells with a stellate phenotype form the juxtacanalicular
layer of the TM. The complete morphogenesis of the TM is
finished around birth [24–27].
These tissue developments require specific gene regu-
latory networks in which many transcription factors and
molecular signals are involved. Although the detailed de-
velopmental networks are still not well defined, some con-
tributing factors are known. Cvekl and Tamm performed
a comprehensive review of the transcription factors that
are associated with the anterior segment morphogenesis
[26]. They include PAX6, PITX2, PITX3, FOXC1, FOXE3,
LMX1B, and MAF, where PAX6 is the essential regulator
for eye development in different organisms [26, 28, 29].
It is involved in controlling neural crest migration and
thus has a critical role in early formation of the CE
and TM [30, 31]. The CE did not develop in Pitx2−/−
and Foxc1−/− mice and the TM was abnormally formed
[32–35]. LMX1B was shown to have a direct link to the
dysgenesis of the TM [36]. Whilst these transcription factors
clearly have an important role, some other transcription
factors also influence CE and TM development [37–41]. In
addition, specific signaling molecules also play a key role
in coordinating the anterior segment growth. This is borne
out with transforming growth factor (TGF)-beta 2 knockout
mice which developed a much thinner cornea with CE failing
to develop [42, 43]. Moreover, heterozygous deficiency of
BMP4 resulted in absent or hypoplastic TM and Schlemm’s
canal, and profound extracellular matrix deficiencies in the
TM [44]. For the role of different growth factors during
embryogenesis and differentiation of the eye, readers are
referred to the review by Tripathi et al. [45].
4. Biological Properties of CE and TMCells
4.1. Cellular Characteristics and Markers Identification. CE
cells adjoin one another with extensive interdigitations and
are interconnected by tight and gap junctions. The tight
junctions do not completely encircle the cells so that the
endothelium can allow selective permeability for nutrients.
The apical sides of the cells contain a band of actin filaments
which helps maintain cell shape and barrier function and
facilitate cell migration in wound healing [46]. Ultra-
structurally, the endothelial cells have a large nucleus and
contain numerous mitochondria, a prominent endoplasmic
reticulum and Golgi apparatus, which are the characteristic
features for cells metabolically active in transport, synthesis,
and secretory function [18].
Although the CE is named “endothelium,” it differs
from the vascular endothelium. The CE is derived from
the neural crest, whereas the vascular endothelium is from
the mesoderm [25]. Additionally, the CE does not contain
Weibel-Palade bodies nor express factor VIII, which are the
typical vascular endothelium markers [47]. The CE displays
an unusual combination of immunoreactions to antibodies
against intermediate filaments vimentin and neurofilaments,
as well as neural markers including neural cell adhesion
molecule, neuron specific enolase, and S-100 protein [47–
50]. These observations are not surprising when we trace
back the origin of the CE. However, there have been con-
troversies about the cytokeratin (CK) profile in the CE. CK8
and CK18 expressions in human CE cells were described
in several studies [51–53] but not in others [54, 55].
Merjava et al. proposed that the variable results were due
to different processing approach and antibody sensitivities
[53]. The labeling of CK7 and CK19 in the CE is even more
controversial [51, 55, 56]. To date, there has not been a
specific marker for the CE. One can mainly distinguish them
by their hexagonal morphology and evaluate their function
using an Ussing chamber to measure the transport activity
[57–59].
The TM cells bridge the intertrabecular spaces through
cytoplasmic extensions, and adjacent cells are firmly con-
nected to each other by desmosomes [22]. Electron micro-
scopic studies revealed that gap junctions form the main
intercellular connection between the TM cells [60]. The
major actin distributions in the TM cytoplasm are straight
stress fibers [61]. However, cross-linked actin networks
(CLANs) have also been detected in human and bovine TM
tissues [61, 62]. Similar to CE cells, there are no specific
biomarkers to identify TM cells. It has been shown that the
TM cells express vimentin, non-muscle actin, aquaporin-1,
acetylated and acetoacetylated low-density lipoproteins, and
the alpha-2 adrenergic receptor [49, 63–66]. The expression
of myocilin in TM cells was increased after dexamethasone
treatment [67]. Nevertheless, these proteins are also present
in other cell types, making it difficult to use a single marker
to identify TM cells. Some other potential TM markers
including the matrix GLA protein and chitinase-3-like-1
were reported by other groups [68, 69].
Despite the lack of specific marker proteins, the TM cells
possess some typical physiological characteristics. Rohen and
Van der Zypen was the first to show that TM cells have
phagocytic capacity [70]. It is believed that the phagocytosis
helps remove debris in the circulating aqueous humour [71].
Besides, meshwork cells can synthesize a variety of extra-
cellular materials including collagens, glycoproteins, and
glycosaminoglycans (see [72] for review). The replacement
and modification of the extracellular matrix compensates
the gradual washout of materials during aqueous perfusion,
so that the necessary outflow resistance is maintained.
Moreover, the presence of contractile filaments in the TM
cell cytoplasm indicates their contractility [73, 74]. It was
found that substances that contract meshwork cells decrease
the aqueous outflow facility and vice versa [75].
Both the CE and TM cells are exposed to continuous
workload throughout lifetime, yet, they have limited pro-
liferative capacity in situ to replace lost cells under normal
circumstances [76, 77]. In the CE, the surrounding cells
spread and slide to fill the gaps caused by cell loss. The
endothelial cells are arrested in G1-phase of the cell cycle
[76]. Bovine TM cells were also shown to be locked in
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Figure 2: (a) Corneal endothelial and (b) trabecular meshwork cells cultured in vitro.
G0/G1-phase [77]. Although both cell types can be grown in
culture, they are contact inhibited [76]. The division rate of
bovine TM cells decreased to negligible amounts when they
were in contact and formed gap junctions [78].
4.2. Consequence of Cell Loss or Malfunction. There are
approximately 4,000 CE cells per mm2 at birth, but the
cell density decreases with age at a rate of 0.6% per year
throughout life [79]. The cell number is usually adequate to
maintain normal corneal function for a lifetime. However,
besides the factor of ageing, endothelial cell loss can also
occur due to disease, trauma, and surgery. These may result
in a higher cell depletion rate than normal, leading to
endothelial failure and hence, loss of visual acuity. In order
to maintain adequate corneal function, a minimum level of
400 to 700 endothelial cells per mm2 is required and the cells
need to be of uniform size and shape [18]. Hence, corneas for
grafting need to be screened for endothelial health and cell
numbers before they are accepted. Some ocular diseases are
manifested by abnormal endothelial cells. Fuch’s endothelial
dystrophy is a corneal disease involving malfunction of the
endothelial cells, in which irregular warts or excrescences
of Descemet’s membrane are secreted. The excrescences are
collagenous secretions (known as guttata) deposited at the
posterior surface of the membrane, causing disruption of the
overlying endothelial cells and thus compromise endothelial
function [18, 80]. Another disease attributable to aberrant
CE is the iridocorneal endothelial (ICE) syndrome. The
endothelium proliferates and migrates outward to the TM
and across the angle onto the surface of the iris, which
may progress to glaucoma, corneal decompensation, or both
[81, 82].
The TM cellularity decreases with age as well. Alvarado
et al. reported a cell loss rate of 0.58% per year [83]. This
is comparable to that seen in the CE. It was estimated that
there were 750,000 cells in the meshwork at 20 years of
age but the number decreased down to around 400,000 by
80 years [84]. Other age-related changes in the TM include
trabecular thickening, trabecular fusions, and alterations to
the extracellular material in the juxtacanalicular meshwork;
all of which would increase the aqueous outflow resistance
and subsequently the intraocular pressure (IOP) [71]. Patho-
logically elevated intraocular pressure is the major risk factor
in primary open angle glaucoma (POAG). Indeed, these age-
related changes are intimately linked to the glaucomatous
alterations found in POAG patients. The glaucomatous
eyes were found to have significantly more cellular losses
compared with age-matched normal eyes [85]. This is
believed to precipitate the decrease in drainage facility. When
cell loss is progressive, trabecular thickening and fusion
may develop due to adhesions of the denuded portions of
the trabeculae. Furthermore, accumulation of extracellular
materials and meshwork cell hyperplasia in glaucomatous
TM that are believed to obstruct the outflow pathway was
also documented [71]. Hence, TM cells are essential to
maintain a healthy meshwork for aqueous drainage.
4.3. Culture In Vitro. In spite of the restricted replication
capacity in vivo, the CE and TM cells can be grown in
culture under appropriate conditions. Figure 2 shows the
in vitro culture of bovine CE and TM cells. It has been
demonstrated that fibroblast growth factor (FGF) stimulates
the proliferation of CE and TM cells [86–88]. Hepatocyte
growth factor (HGF) is also a competent mitogen for both
CE and TM cells in a dose-dependent manner [89, 90].
Culturing of CE cells on dishes coated with collagen type
IV, laminin, or fibronectin favoured the formation of a
typical hexagonal monolayer [86]. Hyldahl reported that
the addition of insulin-like growth factor-1 (IGF-1) and
epidermal growth factor (EGF) stimulates CE cells to initiate
DNA synthesis [91]. Treatment of TM cells with platelet-
derived growth factor (PDGF) can also increase their cell
division. Besides, it enhances the phagocytic activity and
promotes extracellular matrix secretion [92]. IGF-1 was
shown to promote the incorporation of [3H] thymidine in
TM cells, whereas vascular endothelial cell growth factor
(VEGF) restrained cell growth [93]. Studies have revealed
that TGF-beta, which is present in the aqueous humour,
inhibits TM cell proliferation and suppresses S-phase entry of
CE cells [94, 95]. Table 1 shows a summary of the mentioned
growth factors effects on CE and TM cell proliferation in
vitro.
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Table 1: The influence of growth factors on CE and TM cell prolif-
eration.
Growth factor Corneal endothelium Trabecular meshwork
EGF ++ ++
bFGF + ++
HGF + ++
PDGF ++ +
IGF-1 + +
TGF − −−
VEGF −
Both the CE and TM cells are unique cell types in the eye.
They do not normally replace themselves once they are lost
in aging or diseases. To date, there has been no cell therapy
for the treatment of CE and TM related diseases. A lot of
unknown facts about the regenerative capacity of TM or CE
still exist. Thus, the potential to repair or replace the CE and
TM is an important area that needs to be explored.
5. Evidence of Stem-Like Cells in the Schwalbe’s
Ring and Their Therapeutic Implication
Stem cells are undifferentiated cells which can renew them-
selves indefinitely and produce one or more progenies
through symmetric and asymmetric division, whereas pro-
genitor cells have relatively limited self-renewal capacity
and more restricted differentiation abilities. As mentioned
earlier, stem/progenitor cells have been identified in various
adult mammalian tissues. They are crucial for tissue renewal
and regeneration. These adult stem cells have some key
characteristics, including small cell size and high nucleus to
cytoplasm ratio, high proliferative potential, slow cell cycle,
and poor differentiation capacity with primitive cytoplasm
[96]. They reside within a specialized microenvironment
called niche, which offers protection and nourishment to the
cells [97]. It is believed that adult stem cells have huge ethical
and immunological advantages over embryonic stem cells as
a future therapeutic option.
In the eye, accumulating evidence reveals that there is
a population of stem-like cell located in the transition area
between the periphery of the CE and the anterior nonfiltering
portion of the TM (Figure 3). This transition region is
referred to as Schwalbe’s Ring. Schwalbe’s line marks the
peripheral termination of the Descemet’s membrane and can
be viewed clinically in gonioscopy (Figure 1(b)). In 1982,
Raviola identified a population of unusual cells located just
beneath the Schwalbe’s line in rhesus monkey, which she
called Schwalbe’s line cells [98]. These cells are different from
the typical CE and TM cells and have distinct ultrastructural
features. As described, these cells “form a discontinuous
cord, oriented circumferentially at the corneal periphery
and deep to the CE lining of the anterior chamber.” They
morphologically resembled whorled multilamellar bodies of
type II alveolar epithelial cells of the lung and were proposed
to be secretory. Stone et al. found that these cells were
immunoreactive to neuron-specific enolase, suggesting that
they may have neuroregulatory function in the anterior
segment [99]. Rittig and colleagues later reported intense
staining of the enzyme hyaluronan synthase in Schwalbe’s
line cells, indicating their hyaluronan production ability
[100]. Samuelson et al. documented Schwalbe’s line cells in
canine eyes as well [101]. In general, there seems to be a
distinct cell population in the transition area, while their
function is still unclear.
Not much attention was paid to Schwalbe’s line cells
until there was more evidence supporting the presence of
stem/progenitor cells in this transition zone. The idea came
primarily from the observation of an increase in TM cell
division localized to the anterior nonfiltering portion of the
TM after argon laser trabeculoplasty (ALT) [102]. ALT is
a glaucoma therapy which aims at lowering the IOP. The
principle of this laser procedure is not tomake drainage holes
through the TM, but to “blanch” the tissue which creates
superficial burn restricted to the uveal meshwork [103]. The
exact mechanism by which this treatment lowers IOP is not
known, however, one of the possible mechanisms of action
is the repopulation of the TM by stimulating cell division
[104]. Indeed, several studies have shown marked tritiated
thymidine incorporation into the TM cells following ALT
in different species [102, 105, 106]. Acott and colleagues
demonstrated a four-fold increase in TM cell division
in human laser-treated explants compared with untreated
controls [102]. They found that more than 60% of the cell
division was initially localized to the anterior nonfiltering
region of the TM and these proliferative cells migrated to
repopulate the burn lesions afterwards. It appears that these
cells are putative stem cells that are invigorated after ALT to
repopulate the TM, possibly through the release of growth
factors and cytokines. Due to their location at the insertion
region into the cornea just beneath Schwalbe’s line, Kelley
have named them the “TM insert cells” [107].
Although ALT can lower the IOP successfully and, to
some extent, repopulate the cell-deficient TM in glaucoma,
uncontrolled repair process that occurred in the tissue may
become a detrimental consequence. An abnormal corneal
and/or trabecular endothelial cell sheet covering the anterior
uveal meshwork was observed in some glaucoma patients
after ALT [108, 109]. In some cases, they can grow extensively
and block the aqueous outflow subsequently, leading to
the failure of the surgery. Alexander et al. observed this
aberrant endothelial membrane as well in normal human
TM which was subjected to ALT [110]. They found that
laser placed close to Schwalbe’s line advanced the endothelial
extension. It was believed that these repopulating processes
after ALT involve migration of a specialized population of
cells extending from the Schwalbe’s line region [109, 110].
In addition to the observations in the TM, a significantly
higher cell density at the peripheral CE also suggests that
stem-like cells may be present in the peripheral transition
region to provide differentiated CE cells [111, 112]. Other-
wise, the cell density should be uniform all over the CE. It has
been documented in the literature that at least some CE cells
have the ability to divide under specific circumstances [113–
116]. It was found that the peripheral CE cells retained higher
replication competence than those in the central and this
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Figure 3: Scanning electron micrographs of (a) human and (b) bovine eyes, showing the transition between the peripheral cornea and
anterior portion of the trabecular meshwork. There is a distinct transition area in the human tissue but the transition is more abrupt in the
bovine one. The samples were coated with gold and imaged at an accelerating voltage of 4 kV and a working distance of 8mm using a SE2
detector (Gemini LEO 1550 SEM). Scale bar = 20 μm.
was independent on the donor age [117]. Moreover, corneal
grafts in hosts who retain the peripheral endothelium survive
much longer than grafts in hosts with CE cell loss [118].
Persistent precursors from the host cornea may explain
the enhanced long-term survival of grafts. Interestingly,
Balachandran et al. reported in a case series that in spite
of complete graft detachment after Descement membrane
endothelial keratoplasty, spontaneous recovery of corneal
transparency was observed in two patients [119]. They
suggested that “endothelial transfer, migration, regeneration,
or a combination thereof from either the donor or the recipi-
ent may explain the visual recovery.” Schwartzkopff et al. later
reported in vivo re-endothelialization following complete
endothelial cell loss of the grafted donor cornea in rats and
suggested that peripheral CE cells in recipients can support
the regeneration [120]. These findings indicate that CE
may have some sort of regenerative capacity under specific
conditions, which is not consistent with the long-term belief
that they do not divide in vivo [76]. In particular, the
peripheral CE seems to be the regenerative zone in these
conditions. As such, research of the Schwalbe’s Ring region
has become even more interesting, as the precursor cells in
this transition area may be able to supply new cells for both
the TM and CE.
In recent years, molecular marker studies supply more
supportive data for the stem cell niche at the transition
zone. Whikehart et al. detected telomerase activity, which
is a stem cell maker, in the peripheral cornea [121]. They
also observed bromodeoxyuridine (BrdU) labeling, which is
a marker for cell division, in the TM and posterior limbus.
The BrdU incorporation increased and extended into the
CE in response to mechanical wounding. McGowan et al.
showed that cells at the transition region express stem cell
makers nestin, alkaline phosphatase, and telomerase [122].
Following corneal wounding, additional putative stem cell
markers (Oct3/4, Wnt1) and differentiation markers (Pax6,
Sox2) were observed. It was suggested that the putative stem
cells in the transition area migrated to renew the wounded
CE. To date, there has been no specific marker for this
population of putative stem cells despite the observation
of a different immunohistochemical profile in the CE, TM
insert cells, and TM cells. Neuron-specific enolase was found
to locate at the anterior but not posterior portion of the
human TM [49]. Ankyrin G and human milk fat globule
protein (HMFG, also known as breast antigen 46) were
highly expressed in the insert cells. On the contrary, YKL-40
(also known as chitinase-3-like-1 or cartilage glycoprotein-
39) had lower expression levels when compared to the CE
and TM [107, 123].
Ideally, if the molecular signature of the stem-like cells is
known, one can isolate and enrich the stem cell pool rela-
tively easily using fluorescence-activated cell sorting (FACS)
or magnetic immunosorting. However, the search of the
specific stem cell signature will involve a laborious process
and screening of a huge amount of putative markers. Hence,
attempts have been made to isolate and propagate undif-
ferentiated progenitor cells using a sphere culture protocol
[124–126]. Precursors from human and rabbit CE have been
successfully isolated using the sphere-forming assay and it
was found that the peripheral CE contained significantly
more precursors than the central region [127–130]. Mimura
et al. proved that this culture assay selectively isolated
younger progenies [131]. Huang and colleagues showed that
bovine CE cells resembled bovine aorta in its content of
endothelial colony forming cells [132]. Our sphere culture
of primary peripheral bovine CE cells revealed the presence
of undifferentiated precursor cells with self-renewal capacity
and their potential to differentiate into neuronal lineages
(Figures 4 and 5). Besides the CE, progenitor spheres were
also isolated from human TM primary cultures [133]. It is
likely that these isolated precursors from the CE and TM
are from the transition zone in between them. It remains to
be determined whether “Schwalbe’s Line cells”, “TM insert
cells,” and precursors having been isolated are the same cell
type. For our convenience we have called the progenitor cells
“PET cells” (Progenitors for Endothelium and Trabeculum)
so not to presume until proven that we have the exact same
cell population previously described.
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Figure 4: Sphere culture of bovine peripheral corneal endothelial cells. (a) Floating spheres on day 7 in defined serum-free media.
Aggregation and development of dark cores can occur when spheres are left over the optimal culturing period of 5–7 days. (b) Cells migrating
from an attached sphere on adherent substrate. The arrowheads show the contour of the sphere. (c) Nestin (green: undifferentiated cell
marker) and (d) β-III tubulin (red: neuronal marker) staining were detected in the cells that migrated from the primary spheres. Nuclei were
counterstained with DAPI (blue). Insets are negative controls with nonimmunized IgG. (a–c) Scale bar = 100 μm; (d) Scale bar = 50 μm.
Figure 5: After 7 days of differentiation, cells derived from the sphe-
res also expressed β-III tubulin. Nuclei were counterstained with
DAPI (blue). The inset is a negative control with nonimmunized
IgG. Scale bar = 50 μm.
The studies of stem cells in the eye have important im-
plications in ocular health and disease treatment. Animal
models using the isolated CE precursors for regeneration
have been documented in several studies [59, 134, 135]. The
PET cells within the transition area may be a promising
cell source for replacing worn-out endothelium in vivo or
boosting the number of endothelial cells in vitro on potential
corneal graft materials. Asmentioned in the previous section,
ICE syndrome is manifested by abnormal proliferative CE
cells that grow and cover the angle. It is tempting to speculate
that the aberrant cells are metaplastic progenitors residing
in the endothelium. Treatments can possibly be developed
by targeting these cells. Besides, we know that the number
of TM cells drops significantly in glaucoma patients, which
precipitates the blockage of the aqueous outflow pathway.
Thus, repopulating the cell-deficient TM using the PET cells
may be a useful treatment to enhance drainage in glaucoma.
6. Summary and Future Directions
Recent progress in stem cell research provides an optimistic
prospect on their use in regenerative medicine and tissue
engineering. Specifically, advances in iPSCs and adult stem
cells research raise hope for personalized cell replacement
therapies. However, before iPSCs can be clinically applied,
extensive efforts are needed to devise reliable production
methods to address the safety concerns. In this paper, we
summarized the accumulating evidence of the presence
of putative stem cells in the transition zone between the
peripheral CE and the anterior extension of the TM. We also
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discussed the origin and biological properties of both CE and
TM cells. Up to now, there has been no clear definition of
the progenitor cells located in the transition area. We have
called the putative stem cells “PET cells” as they have the
potential to replenish both the CE and TM. It remains to
be determined whether the previously described “Schwalbe’s
Line cells” and “TM insert cells”, as well as the precursors
having been isolated, are of the same cell type; if they are,
exactly what proliferation and differentiation potential do
they retain, why do they not seem to repopulate the TM in
glaucoma or the CE in age and disease when these popula-
tions are sorely depleted and finally how can they be used
therapeutically?
Further research is required to establish the protocol to
regulate cell division and differentiation of the PET cells
towards appropriate lineages for repopulation of the diseased
CE and TM. We need to identify which factors and signals
govern their division and differentiation. Another challenge
is the specific biomarker identification of the PET cells,
which would facilitate stem cell isolation and enrichment.
Furthermore, a better understanding of the migration and
settlement properties of the PET cells is also important for
the use of possible bioengineered materials. CE and TM cell
loss is central to a number of ocular conditions including
corneal diseases and glaucoma. In spite of the challenges,
PET cells represent an attractive therapeutic stem cell source
for the regeneration of the CE and TM. It is hoped that future
research will ultimately lead to the development of stem-
cell-based therapies for CE diseases and glaucoma, which
can reduce the requirement for corneal grafts and laser or
surgical treatments in glaucomatous patients.
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